

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssept189dxw

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JAN 02 STN pricing information for 2008 now available
NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified
prophetic substances
NEWS 4 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new
custom IPC display formats
NEWS 5 JAN 28 MARPAT searching enhanced
NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days
of publication
NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8 JAN 28 MEDLINE and LMEEDLINE reloaded with enhancements
NEWS 9 FEB 08 STN Express, Version 8.3, now available
NEWS 10 FEB 20 PCI now available as a replacement to DPCI
NEWS 11 FEB 25 IFIREF reloaded with enhancements
NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements
NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current
U.S. National Patent Classification
NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom
IPC display formats
NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental
spectra
NEWS 16 MAR 31 CA/CAPLUS and CASREACT patent number format for U.S.
applications updated
NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI
NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued
NEWS 20 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new
predefined hit display formats
NEWS 21 APR 28 EMBASE Controlled Term thesaurus enhanced
NEWS 22 APR 28 IMSRESEARCH reloaded with enhancements
NEWS 23 MAY 30 INPAFAMDB now available on STN for patent family
searching
NEWS 24 MAY 30 DGENE, PCTGEN, and USGENE enhanced with new homology
sequence search option
NEWS 25 JUN 06 EPFULL enhanced with 260,000 English abstracts
NEWS 26 JUN 06 KOREAPAT updated with 41,000 documents
NEWS 27 JUN 13 USPATFULL and USPAT2 updated with 11-character
patent numbers for U.S. applications
NEWS 28 JUN 19 CAS REGISTRY includes selected substances from
web-based collections

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 20:53:41 ON 20 JUN 2008

=> index bioscience

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

0.21	0.21
------	------

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 20:53:49 ON 20 JUN 2008

69 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0* with SET DETAIL OFF.

=> s lactoperoxidase and osteo?

1	FILE AGRICOLA
9	FILE BIOSIS
1	FILE BIOTECHABS
1	FILE BIOTECHDS
2	FILE BIOTECHNO
3	FILE CABA
13	FILE CAPLUS
22 FILES SEARCHED...	
1	FILE DGENE
2	FILE DRUGU
10	FILE EMBASE
2	FILE ESBIODASE
3	FILE FROSTI
3	FILE FSTA
4	FILE IFIPAT
2	FILE LIFESCI
5	FILE MEDLINE
1	FILE PASCAL
2	FILE PROMT
5	FILE SCISEARCH
3	FILE TOXCENTER
60 FILES SEARCHED...	
587	FILE USPATFULL
97	FILE USPAT2
8	FILE WPIDS
8	FILE WPINDEX

24 FILES HAVE ONE OR MORE ANSWERS, 69 FILES SEARCHED IN STNINDEX

L1 QUE LACTOPEROXIDASE AND OSTEO?

=> s l1 and (food or drink or drug or feed)

```
1 FILE BIOSIS
1 FILE BIOTECHNO
1 FILE CABA
5 FILE CAPLUS
1 FILE DGENE
1 FILE DRUGU
27 FILES SEARCHED...
7 FILE EMBASE
1 FILE FSTA
2 FILE IFIPAT
1 FILE MEDLINE
2 FILE PROMT
1 FILE SCISEARCH
1 FILE TOXCENTER
59 FILES SEARCHED...
475 FILE USPATFULL
84 FILE USPAT2
6 FILE WPIDS
6 FILE WPINDEX
```

17 FILES HAVE ONE OR MORE ANSWERS, 69 FILES SEARCHED IN STINDEX

L2 QUE L1 AND (FOOD OR DRINK OR DRUG OR FEED)

=> file biosis biotechno caba caplus dgene drugu embase fsta ifipat medline promt
scisearch toxcenter uspatfull uspat2
COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	2.60	2.81

FILE 'BIOSIS' ENTERED AT 20:56:16 ON 20 JUN 2008

Copyright (c) 2008 The Thomson Corporation

FILE 'BIOTECHNO' ENTERED AT 20:56:16 ON 20 JUN 2008

COPYRIGHT (C) 2008 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 20:56:16 ON 20 JUN 2008

COPYRIGHT (C) 2008 CAB INTERNATIONAL (CABI)

FILE 'CAPLUS' ENTERED AT 20:56:16 ON 20 JUN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 20:56:16 ON 20 JUN 2008

COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'DRUGU' ENTERED AT 20:56:16 ON 20 JUN 2008

COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'EMBASE' ENTERED AT 20:56:16 ON 20 JUN 2008

Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'FSTA' ENTERED AT 20:56:16 ON 20 JUN 2008

COPYRIGHT (C) 2008 International Food Information Service

FILE 'IFIPAT' ENTERED AT 20:56:16 ON 20 JUN 2008

COPYRIGHT (C) 2008 IFI CLAIMS(R) Patent Services (IFI)

FILE 'MEDLINE' ENTERED AT 20:56:16 ON 20 JUN 2008

FILE 'PROMT' ENTERED AT 20:56:16 ON 20 JUN 2008
COPYRIGHT (C) 2008 Gale Group. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 20:56:16 ON 20 JUN 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'TOXCENTER' ENTERED AT 20:56:16 ON 20 JUN 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 20:56:16 ON 20 JUN 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 20:56:16 ON 20 JUN 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

```
=> s l2
L3          584 L2
```

```
=> rem dup l3
DUP IS NOT VALID HERE
The DELETE command is used to remove various items stored by the
system.
```

To delete a saved query, saved answer set, saved L-number list, SDI request, batch request, mailing list, or user-defined cluster, format, or search field, enter the name. The name may include ? for left, right, or simultaneous left and right truncation.

Examples:

DELETE BIO?/Q	- delete query names starting with BIO
DELETE ?DRUG/A	- delete answer set names ending with DRUG
DELETE ?ELEC?/L	- delete L-number lists containing ELEC
DELETE ANTICOAG/S	- delete SDI request
DELETE ENZYME/B	- delete batch request
DELETE .MYCLUSTER	- delete user-defined cluster
DELETE .MYFORMAT	- delete user-defined display format
DELETE .MYFIELD	- delete user-defined search field
DELETE NAMELIST MYLIST	- delete mailing list

To delete an ordered document or an offline print, enter its number.

Examples:

DELETE P123001C	- delete print request
DELETE D134002C	- delete document order request

To delete an individual L-number or range of L-numbers, enter the L-number or L-number range. You may also enter DELETE LAST followed by a number, n, to delete the last n L-numbers. RENUMBER or NORENUMBER may also be explicitly specified to override the value of SET RENUMBER.

Examples:

DELETE L21	- delete a single L-number
DELETE L3-L6	- delete a range of L-numbers
DELETE LAST 4	- delete the last 4 L-numbers
DELETE L33-	- delete L33 and any higher L-number
DELETE -L55	- delete L55 and any lower L-number

DELETE L2-L6 RENUMBER - delete a range of L-numbers and
 renumber remaining L-numbers
 DELETE RENUMBER - renumber L-numbers after deletion of
 intermediate L-numbers

Entire sets of saved items, SDI requests, batch requests, user-defined items, or E-numbers can be deleted.

Examples:

DELETE SAVED/Q - delete all saved queries
 DELETE SAVED/A - delete all saved answer sets
 DELETE SAVED/L - delete all saved L-number lists
 DELETE SAVED - delete all saved queries, answer sets,
 and L-number lists
 DELETE SAVED/S - delete all SDI requests
 DELETE SAVED/B - delete all batch requests
 DELETE CLUSTER - delete all user-defined clusters
 DELETE FORMAT - delete all user-defined display formats
 DELETE FIELD - delete all user-defined search fields
 DELETE SELECT - delete all E-numbers
 DELETE HISTORY - delete all L-numbers and restart the
 session at L1

To delete an entire multifile SDI request, enter DELETE and the name of the request. To delete a component from the multifile SDI, enter DELETE and the name of the component.

```
=> dup rem l3
DUPLICATE IS NOT AVAILABLE IN 'DGENE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L3
L4      581 DUP REM L3 (3 DUPLICATES REMOVED)

=> s l4 and digest?
L5      474 L4 AND DIGEST?

=> s l5 and osteoblast?
L6      107 L5 AND OSTEOBLAST?

=> s l6 and promot?
L7      103 L6 AND PROMOT?

=> s l7 and induc?
L8      98 L7 AND INDUC?

=> s l8 and osteogenesis
L9      28 L8 AND OSTEOGENESIS

=> d 19 1-28

L9  ANSWER 1 OF 28  USPATFULL on SIN
AN  2008:137337  USPATFULL
TI  Osteoblast Growth Factor
IN  Phan, Tuan, Success, AUSTRALIA
    Xu, Jiake, Karrinyup, AUSTRALIA
    Zheng, Ming Hao, City Beach, AUSTRALIA
PI  US 20080119406      A1  20080522
AI  US 2005-587218      A1  20050413 (11)
    WO 2005-AU526        20050413
                                20070813  PCT 371 date
PRAI AU 2004-2004902048  20040419
```

DT Utility
FS APPLICATION
LN.CNT 2550
INCL INCLM: 514/012.000
INCLS: 514/013.000; 514/014.000; 514/015.000
NCL NCLM: 514/012.000
NCLS: 514/013.000; 514/014.000; 514/015.000
IC IPCI A61K0038-00 [I,A]; A61P0019-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 2 OF 28 USPATFULL on SIN
AN 2007:334990 USPATFULL
TI HUMAN CDNAS AND PROTEINS AND USES THEREOF
IN BEJANIN, STEPHANE, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PI US 20070292885 A1 20071220
AI US 2007-831468 A1 20070731 (11)
RLI Continuation of Ser. No. US 2004-838854, filed on 3 May 2004, GRANTED,
Pat. No. US 7291495 Division of Ser. No. US 2001-489, filed on 14 Nov
2001, GRANTED, Pat. No. US 6794363 Division of Ser. No. US 2001-924340,
filed on 6 Aug 2001, GRANTED, Pat. No. US 7074901
PRAI WO 2001-1B1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)

DT Utility
FS APPLICATION
LN.CNT 26802
INCL INCLM: 435/006.000
INCLS: 435/320.100; 435/325.000; 435/069.100; 435/007.100; 530/300.000;
530/387.900; 536/023.100
NCL NCLM: 435/006.000
NCLS: 435/007.100; 435/069.100; 435/320.100; 435/325.000; 530/300.000;
530/387.900; 536/023.100
IC IPCI C12Q0001-68 [I,A]; C07H0021-00 [I,A]; C07K0016-00 [I,A];
C07K0002-00 [I,A]; G01N0033-53 [I,A]; C12N0015-63 [I,A];
C12N0005-00 [I,A]; C12P0021-00 [I,A]
IPCR C12Q0001-68 [I,C]; C12Q0001-68 [I,A]; C07H0021-00 [I,C];
C07H0021-00 [I,A]; C07K0002-00 [I,C]; C07K0002-00 [I,A];
C07K0016-00 [I,C]; C07K0016-00 [I,A]; C12N0005-00 [I,C];
C12N0005-00 [I,A]; C12N0015-63 [I,C]; C12N0015-63 [I,A];
C12P0021-00 [I,C]; C12P0021-00 [I,A]; G01N0033-53 [I,C];
G01N0033-53 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 28 USPATFULL on SIN
AN 2007:48142 USPATFULL
TI WISP polypeptides and nucleic acids encoding same
IN Botstein, David, Belmont, CA, UNITED STATES
Cohen, Robert L., San Mateo, CA, UNITED STATES
Goddard, Audrey D., San Francisco, CA, UNITED STATES
Gurney, Austin L., Belmont, CA, UNITED STATES
Hillan, Kenneth J., San Francisco, CA, UNITED STATES
Lawrence, David A., San Francisco, CA, UNITED STATES
Levine, Arnold J., New York, NY, UNITED STATES
Pennica, Diane, Burlingame, CA, UNITED STATES
Roy, Margaret Ann, San Francisco, CA, UNITED STATES
Wood, William I., Hillsborough, CA, UNITED STATES
PI US 20070041964 A1 20070222
AI US 2006-488375 A1 20060717 (11)
RLI Division of Ser. No. US 2002-112267, filed on 27 Mar 2002, GRANTED, Pat.

No. US 7101850 Division of Ser. No. US 1998-182145, filed on 29 Oct 1998, GRANTED, Pat. No. US 6387657

PRAI US 1997-63704P 19971029 (60)
US 1998-73612P 19980204 (60)
US 1998-81695P 19980414 (60)

DT Utility
FS APPLICATION
LN.CNT 9316
INCL INCLM: 424/131.100
INCLS: 424/146.100; 530/387.200; 530/388.260
NCL NCLM: 424/131.100
NCLS: 424/146.100; 530/387.200; 530/388.260
IC IPCI A61K0039-395 [I,A]; C07K0016-40 [I,A]; C07K0016-42 [I,A]
IPCR A61K0039-395 [I,C]; A61K0039-395 [I,A]; C07K0016-40 [I,C];
C07K0016-40 [I,A]; C07K0016-42 [I,C]; C07K0016-42 [I,A]

L9 ANSWER 4 OF 28 USPATFULL on SIN
AN 2006:247698 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA Serono Genetics Institute S.A., Evry, FRANCE (non-U.S. corporation)
PI US 20060211090 A1 20060921
AI US 2006-412325 A1 20060427 (11)
RLI Division of Ser. No. US 2002-154678, filed on 22 May 2002, PENDING
Continuation-in-part of Ser. No. US 2001-924340, filed on 6 Aug 2001,
GRANTED, Pat. No. US 7074901

PRAI US 2001-293574P 20010525 (60)
US 2001-298698P 20010615 (60)
US 2001-302277P 20010629 (60)
US 2001-305456P 20010713 (60)

DT Utility
FS APPLICATION
LN.CNT 20353
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC IPCI C07K0014-47 [I,A]; C07K0014-435 [I,C*]; C07H0021-04 [I,A];
C07H0021-00 [I,C*]; C12P0021-06 [I,A]
IPCR C07K0014-435 [I,C]; C07K0014-47 [I,A]; G01N0033-50 [I,C*];
G01N0033-50 [I,A]; A61K0038-00 [N,C*]; A61K0038-00 [N,A];
A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61K0048-00 [N,C*];
A61K0048-00 [N,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A];
A61P0035-02 [I,A]; A61P0035-04 [I,A]; A61P0043-00 [I,C*];
A61P0043-00 [I,A]; C07H0021-00 [I,C]; C07H0021-04 [I,A];
C07K0016-18 [I,C*]; C07K0016-18 [I,A]; C12N0015-09 [I,C*];
C12N0015-09 [I,A]; C12N0015-12 [I,C*]; C12N0015-12 [I,A];
C12P0021-02 [I,C*]; C12P0021-02 [I,A]; C12P0021-06 [I,C];
C12P0021-06 [I,A]; C12Q0001-68 [I,C*]; C12Q0001-68 [I,A];
G01N0033-15 [I,C*]; G01N0033-15 [I,A]; G01N0033-53 [I,C*];
G01N0033-53 [I,A]; G01N0033-566 [I,C*]; G01N0033-566 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 28 USPATFULL on SIN
AN 2006:144853 USPATFULL
TI Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and
integrin alpha subunit protein and nucleic acid molecules and uses
thereof
IN McCarthy, Sean A., San Diego, CA, UNITED STATES
Gearing, David P., Camberwell, AUSTRALIA
Holtzman, Douglas A., Seattle, WA, UNITED STATES

Pan, Yang, Bellevue, WA, UNITED STATES
 Busfield, Samantha J., Victoria Park, AUSTRALIA
 Barnes, Thomas M., Brookline, MA, UNITED STATES
 Mackay, Charles R., Vaucluse, AUSTRALIA
 Lora, Jose M., Mountain View, CA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
 PI US 20060122373 A1 20060608
 AI US 2005-175714 A1 20050705 (11)
 RLI Continuation-in-part of Ser. No. US 2003-417719, filed on 17 Apr 2003,
 ABANDONED Continuation of Ser. No. US 2000-568218, filed on 9 May 2000,
 ABANDONED Continuation-in-part of Ser. No. US 1997-872855, filed on 11
 Jun 1997, GRANTED, Pat. No. US 6121045 Continuation-in-part of Ser. No.
 US 1997-832633, filed on 4 Apr 1997, ABANDONED Continuation-in-part of
 Ser. No. US 2004-895676, filed on 21 Jul 2004, PENDING Continuation of
 Ser. No. US 2002-105934, filed on 25 Mar 2002, ABANDONED Continuation of
 Ser. No. US 2001-862972, filed on 22 May 2001, ABANDONED Continuation of
 Ser. No. US 1998-62389, filed on 17 Apr 1998, ABANDONED
 Continuation-in-part of Ser. No. US 2002-95407, filed on 11 Mar 2002,
 ABANDONED Continuation of Ser. No. US 1999-451828, filed on 30 Nov 1999,
 ABANDONED Division of Ser. No. US 1998-128155, filed on 3 Aug 1998,
 GRANTED, Pat. No. US 6117654 Continuation-in-part of Ser. No. US
 2002-126560, filed on 19 Apr 2002, ABANDONED Continuation-in-part of
 Ser. No. US 1999-237571, filed on 26 Jan 1999, ABANDONED
 Continuation-in-part of Ser. No. US 1998-13810, filed on 27 Jan 1998,
 GRANTED, Pat. No. US 6197551 Continuation-in-part of Ser. No. US
 2003-413899, filed on 14 Apr 2003, PENDING Division of Ser. No. US
 2001-940240, filed on 27 Aug 2001, ABANDONED Continuation of Ser. No. US
 1999-248239, filed on 10 Feb 1999, ABANDONED Continuation-in-part of
 Ser. No. US 1998-23664, filed on 10 Feb 1998, ABANDONED
 Continuation-in-part of Ser. No. US 2002-105150, filed on 25 Mar 2002,
 ABANDONED Continuation of Ser. No. US 2002-60680, filed on 30 Jan 2002,
 ABANDONED Continuation of Ser. No. US 1998-57951, filed on 9 Apr 1998,
 ABANDONED Continuation-in-part of Ser. No. US 2003-601368, filed on 23
 Jun 2003, ABANDONED Continuation of Ser. No. US 2000-572003, filed on 15
 May 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-561263,
 filed on 27 Apr 2000, ABANDONED Continuation-in-part of Ser. No. US
 1999-322790, filed on 28 May 1999, ABANDONED

PRAI US 1997-62017P 19971010 (60)
 US 1997-44746P 19970418 (60)
 US 1997-54646P 19970804 (60)
 US 1998-91650P 19980702 (60)

DT Utility
 FS APPLICATION
 LN.CNT 16556
 INCL INCLM: 530/350.000
 INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.500
 NCL NCLM: 530/350.000
 NCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.500

IC IPCI C07K0014-705 [I,A]; C07K0014-715 [I,A]; C07K0014-435 [I,C*];
 C07H0021-04 [I,A]; C07H0021-00 [I,C*]; C12P0021-06 [I,A]
 IPCR C07K0014-435 [I,C]; C07K0014-705 [I,A]; C07H0021-00 [I,C];
 C07H0021-04 [I,A]; C07K0014-715 [I,A]; C12P0021-06 [I,C];
 C12P0021-06 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 6 OF 28 USPATFULL on STN
 AN 2005:30751 USPATFULL
 TI Human CDNAS and proteins and uses thereof
 IN Bejanin, Stephane, Paris, FRANCE
 Tanaka, Hiroaki, Antony, FRANCE
 PI US 20050026182 A1 20050203
 US 7291495 B2 20071106

AI US 2004-838854 AI 20040503 (10)
 RLI Division of Ser. No. US 2001-489, filed on 14 Nov 2001, GRANTED, Pat.
 No. US 6794363 Division of Ser. No. US 2001-924340, filed on 6 Aug 2001,
 PENDING

PRAI WO 2001-IB1715 20010806
 US 2001-305456P 20010713 (60)
 US 2001-302277P 20010629 (60)
 US 2001-298698P 20010615 (60)
 US 2001-293574P 20010525 (60)

DT Utility
 FS APPLICATION
 LN.CNT 25707

INCL INCLM: 435/006.000
 INCLS: 435/069.100; 435/184.000; 435/320.100; 435/325.000; 536/023.200

NCL NCLM: 435/226.000; 435/006.000
 NCLS: 435/070.100; 435/071.100; 435/252.300; 435/252.330; 435/254.100;
 435/320.100; 435/325.000; 435/069.100; 435/184.000; 536/023.200

IC [7]
 ICM C12Q001-68
 ICS C07H021-04; C12N009-99
 IPCI C12Q0001-68 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*];
 C12N0009-99 [ICS,7]
 IPCI-2 C12N0009-64 [I,A]; C12N0015-63 [I,A]; C12N0001-20 [I,A];
 C12N0015-00 [I,A]; C12N0001-15 [I,A]; C12P0021-00 [I,A]
 IPCR C12N0009-64 [I,C]; C12N0009-64 [I,A]; A61K0038-00 [N,C*];
 A61K0038-00 [N,A]; A61K0048-00 [N,C*]; A61K0048-00 [N,A];
 C07K0014-435 [I,C*]; C07K0014-47 [I,A]; C12N0001-15 [I,C];
 C12N0001-15 [I,A]; C12N0001-20 [I,C]; C12N0001-20 [I,A];
 C12N0015-00 [I,C]; C12N0015-00 [I,A]; C12N0015-63 [I,C];
 C12N0015-63 [I,A]; C12P0021-00 [I,C]; C12P0021-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 7 OF 28 USPATFULL on SIN
 AN 2004:66006 USPATFULL
 TI DNA array sequence selection
 IN Lorenz, Matthias, Bethesda, MD, United States
 PA The United States of America as represented by the Department of Health
 and Human Services, Washington, DC, United States (U.S. government)

PI US 6706867 B1 20040316
 AI US 2000-741238 20001219 (9)
 DT Utility
 FS GRANTED
 LN.CNT 23532

INCL INCLM: 536/023.100
 INCLS: 536/024.320; 536/024.310; 536/024.300; 435/006.000

NCL NCLM: 536/023.100
 NCLS: 435/006.000; 536/024.300; 536/024.310; 536/024.320

IC [7]
 ICM C07H021-04
 ICS C12Q001-68
 IPCI C07H0021-04 [ICM,7]; C07H0021-00 [ICM,7,C*]; C12Q0001-68 [ICS,7]
 IPCR C12Q0001-68 [I,C*]; C12Q0001-68 [I,A]

EXF 435/6; 536/24.32; 536/24.31; 536/24.33; 536/23.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 8 OF 28 USPATFULL on SIN
 AN 2003:282611 USPATFULL
 TI Human cDNAs and proteins and uses thereof
 IN Bejanin, Stephane, Paris, FRANCE
 Tanaka, Hiroaki, Antony, FRANCE
 PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
 PI US 20030198954 AI 20031023

US 7122629 B2 20061017
 AI US 2001-1142 A1 20011114 (10)
 RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
 PRAI WO 2001-1B1715 20010806
 US 2001-305456P 20010713 (60)
 US 2001-302277P 20010629 (60)
 US 2001-298698P 20010615 (60)
 US 2001-293574P 20010525 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 25681
 INCL INCLM: 435/006.000
 INCLS: 536/023.200
 NCL NCLM: 530/350.000; 435/006.000
 NCLS: 435/007.100; 536/023.200
 IC [7]
 ICM C12Q001-68
 ICS C07H021-04
 IPCI C12Q0001-68 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*]
 IPCI-2 C07K0001-00 [I,A]; C07K0014-00 [I,A]; C07K0017-00 [I,A]
 IPCR C07K0001-00 [I,C]; C07K0001-00 [I,A]; A61K0038-00 [N,C*];
 A61K0038-00 [N,A]; A61K0048-00 [N,C*]; A61K0048-00 [N,A];
 C07K0014-00 [I,C]; C07K0014-00 [I,A]; C07K0014-435 [I,C*];
 C07K0014-47 [I,A]; C07K0017-00 [I,C]; C07K0017-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 9 OF 28 USPATFULL on STN
 AN 2003:264778 USPATFULL
 TI Morphogen analogs of bone morphogenic proteins
 IN Keck, Peter C., Millbury, MA, UNITED STATES
 Bosokunda, Dattatreyaumurty, Shrewsbury, MA, UNITED STATES
 PA Curis, Inc., Cambridge, MA (U.S. corporation)
 PI US 20030185792 A1 20031002
 AI US 2002-164279 A1 20020606 (10)
 RLI Continuation-in-part of Ser. No. US 2001-791946, filed on 22 Feb 2001,
 PENDING Continuation of Ser. No. US 1997-786284, filed on 22 Jan 1997,
 GRANTED, Pat. No. US 6273598 Continuation-in-part of Ser. No. US
 1996-589552, filed on 22 Jan 1996, ABANDONED
 PRAI US 2002-354820P 20020205 (60)
 US 2002-371298P 20020410 (60)
 US 2001-296291P 20010606 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 4870
 INCL INCLM: 424/085.100
 INCLS: 514/009.000; 514/044.000; 514/012.000; 435/184.000
 NCL NCLM: 424/085.100
 NCLS: 435/184.000; 514/009.000; 514/012.000; 514/044.000
 IC [7]
 ICM A61K038-19
 ICS A61K038-18; A61K038-12; A61K048-00; C12N009-99
 IPCI A61K0038-19 [ICM,7]; A61K0038-18 [ICS,7]; A61K0038-12 [ICS,7];
 A61K0048-00 [ICS,7]; C12N0009-99 [ICS,7]
 IPCR C07K0001-00 [I,C*]; C07K0001-00 [I,A]; C07K0014-435 [I,C*];
 C07K0014-51 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 10 OF 28 USPATFULL on STN
 AN 2003:244219 USPATFULL
 TI Human cDNAs and proteins and uses thereof
 IN Bejanin, Stephane, Paris, FRANCE
 Tanaka, Hiroaki, Antony, FRANCE

PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
 PI US 20030170628 A1 20030911
 US 7094876 B2 20060822
 AI US 2001-999570 A1 20011114 (9)
 RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
 PRAI WO 2001-1B1715 20010806
 US 2001-305456P 20010713 (60)
 US 2001-302277P 20010629 (60)
 US 2001-298698P 20010615 (60)
 US 2001-293574P 20010525 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 25549
 INCL INCLM: 435/006.000
 INCLS: 435/069.100; 435/007.100; 435/320.100; 435/325.000; 530/350.000;
 530/388.100; 536/023.500
 NCL NCLM: 530/350.000; 435/006.000
 NCLS: 435/007.100; 435/069.100; 435/320.100; 435/325.000; 530/388.100;
 536/023.500
 IC [7]
 ICM C12Q001-68
 ICS G01N033-53; C07H021-04; C12P021-02; C12N005-06; C07K014-47
 IPCI C12Q0001-68 [ICM,7]; G01N0033-53 [ICS,7]; C07H0021-04 [ICS,7];
 C07H0021-00 [ICS,7,C*]; C12P0021-02 [ICS,7]; C12N0005-06 [ICS,7];
 C07K0014-47 [ICS,7]; C07K0014-435 [ICS,7,C*]
 IPCI-2 C07K0001-00 [I,A]; C07K0014-00 [I,A]; C07K0017-00 [I,A]
 IPCR A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0048-00 [N,C*];
 A61K0048-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-47 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 11 OF 28 USPATFULL ON STN
 AN 2003:231986 USPATFULL
 TI Human cDNAs and proteins and uses thereof
 IN Bejanin, Stephane, Paris, FRANCE
 Tanaka, Hiroaki, Antony, FRANCE
 PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
 PI US 20030162186 A1 20030828
 US 20070015144 A9 20070118
 AI US 2002-154678 A1 20020522 (10)
 PRAI US 2001-293574P 20010525 (60)
 US 2001-298698P 20010615 (60)
 US 2001-302277P 20010629 (60)
 US 2001-305456P 20010713 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 25533
 INCL INCLM: 435/006.000
 INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200
 NCL NCLM: 435/006.000
 NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200
 IC [7]
 ICM C12Q001-68
 ICS C07H021-04; C12N009-00; C12P021-02; C12N005-06
 IPCI C12Q0001-68 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*];
 C12N0009-00 [ICS,7]; C12P0021-02 [ICS,7]; C12N0005-06 [ICS,7]
 IPCI-2 C12Q0001-68 [I,A]; C07H0021-04 [I,A]; C07H0021-00 [I,C*];
 C12N0009-00 [I,A]; C12P0021-02 [I,A]; C12N0005-06 [I,A]
 IPCR C12Q0001-68 [I,C]; C12Q0001-68 [I,A]; A61K0038-00 [N,C*];
 A61K0038-00 [N,A]; A61K0048-00 [N,C*]; A61K0048-00 [N,A];
 C07H0021-00 [I,C]; C07H0021-04 [I,A]; C07K0014-435 [I,C*];
 C07K0014-47 [I,A]; C12N0005-06 [I,C]; C12N0005-06 [I,A];
 C12N0009-00 [I,C]; C12N0009-00 [I,A]; C12P0021-02 [I,C];

C12P0021-02 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 12 OF 28 USPATFULL on STN
AN 2003:225673 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
PI US 20030157485 A1 20030821
US 6989262 B2 20060124
AI US 2001-992095 A1 20011113 (9)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 25484
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 435/226.000; 800/008.000;
536/023.200; 530/388.260; 435/007.200
NCL NCLM: 435/226.000; 435/006.000
NCLS: 424/094.640; 435/041.000; 435/068.100; 435/252.300; 435/007.200;
435/069.100; 435/320.100; 435/325.000; 530/388.260; 536/023.200;
800/008.000
IC [7]
ICM C12Q001-68
ICS G01N033-53; G01N033-567; A01K067-00; C07H021-04; C12N009-64;
C12P021-02; C12N005-06
IPCI C12Q001-68 [ICM,7]; G01N033-53 [ICS,7]; G01N033-567 [ICS,7];
A01K0067-00 [ICS,7]; C07H021-04 [ICS,7]; C07H0021-00 [ICS,7,C*];
C12N009-64 [ICS,7]; C12P0021-02 [ICS,7]; C12N0005-06 [ICS,7]
IPCI-2 C12N009-64 [I,A]; C12N0001-20 [I,A]; C12P0001-00 [I,A];
C12P0021-06 [I,A]; A61K0038-48 [I,A]; A61K0038-43 [I,C*]
IPCR A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0048-00 [N,C*];
A61K0048-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-47 [I,A];
C12N009-64 [I,A]; A61K0038-43 [I,C]; A61K0038-48 [I,A];
C12N0001-20 [I,C]; C12N0001-20 [I,A]; C12N0009-64 [I,C];
C12P0001-00 [I,C]; C12P0001-00 [I,A]; C12P0021-06 [I,C];
C12P0021-06 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 13 OF 28 USPATFULL on STN
AN 2003:140406 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 20030096247 A1 20030522
US 7005500 B2 20060228
AI US 2001-986 A1 20011114 (10)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION

LN.CNT 25656
 INCL INCLM: 435/006.000
 INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;
 536/023.200; 800/008.000
 NCL NCLM: 530/350.000; 435/006.000
 NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200;
 800/008.000
 IC [7]
 ICM C12Q001-68
 ICS A01K067-00; C07H021-04; C12N009-00; C12P021-02; C12N005-06
 IPCI C12Q0001-68 [ICM,7]; A01K0067-00 [ICS,7]; C07H0021-04 [ICS,7];
 C07H0021-00 [ICS,7,C*]; C12N0009-00 [ICS,7]; C12P0021-02 [ICS,7];
 C12N0005-06 [ICS,7]
 IPCI-2 A61K0038-00 [I,A]
 IPCR A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0048-00 [N,C*];
 A61K0048-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-47 [I,A];
 A61K0038-00 [I,A]; A61K0038-00 [I,C]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 14 OF 28 USPATFULL on STN
 AN 2003:133926 USPATFULL
 TI Human cDNAs and proteins and uses thereof
 IN Bejanin, Stephane, Paris, FRANCE
 Tanaka, Hiroaki, Antony, FRANCE
 PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
 PI US 20030092011 A1 20030515
 US 6794363 B2 20040921
 AI US 2001-489 A1 20011114 (10)
 RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
 PRAI WO 2001-IB1715 20010806
 US 2001-305456P 20010713 (60)
 US 2001-302277P 20010629 (60)
 US 2001-298698P 20010615 (60)
 US 2001-293574P 20010525 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 25607
 INCL INCLM: 435/006.000
 INCLS: 800/003.000; 435/007.900; 435/183.000; 435/069.100; 435/320.100;
 435/325.000; 536/023.200
 NCL NCLM: 514/012.000; 435/006.000
 NCLS: 435/023.000; 530/350.000; 536/023.500; 435/007.900; 435/069.100;
 435/183.000; 435/320.100; 435/325.000; 536/023.200; 800/003.000
 IC [7]
 ICM C12Q001-68
 ICS G01N033-53; G01N033-542; C07H021-04; C12N009-00; C12P021-02;
 C12N005-06
 IPCI C12Q0001-68 [ICM,7]; G01N0033-53 [ICS,7]; G01N0033-542 [ICS,7];
 G01N0033-536 [ICS,7,C*]; C07H0021-04 [ICS,7]; C07H0021-00
 [ICS,7,C*]; C12N0009-00 [ICS,7]; C12P0021-02 [ICS,7]; C12N0005-06
 [ICS,7]
 IPCI-2 C12Q0001-37 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*];
 C07K0014-00 [ICS,7]; A61K0038-00 [ICS,7]
 IPCR A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0048-00 [N,C*];
 A61K0048-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-47 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 15 OF 28 USPATFULL on STN
 AN 2003:99573 USPATFULL
 TI WISP polypeptides and nucleic acids encoding same
 IN Levine, Arnold J., Princeton, NJ, UNITED STATES
 Pennica, Diane, Burlingame, CA, UNITED STATES

PA Genentech, Inc. (U.S. corporation)
 PI US 20030068678 A1 20030410
 US 7101850 B2 20060905
 AI US 2002-112267 A1 20020327 (10)
 RLI Division of Ser. No. US 1998-182145, filed on 29 Oct 1998, GRANTED, Pat.
 No. US 6387657
 PRAI US 1997-63704P 19971029 (60)
 US 1998-73612P 19980204 (60)
 US 1998-81695P 19980414 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 9734
 INCL INCLM: 435/069.100
 INCLS: 435/320.100; 435/325.000; 536/023.500; 435/183.000
 NCL NCLM: 514/012.000; 435/069.100
 NCLS: 530/350.000; 435/183.000; 435/320.100; 435/325.000; 536/023.500
 IC [7]
 ICM C07H021-04
 ICS C12N009-00; C12P021-02; C12N005-06
 IPCI C07H0021-04 [ICM,7]; C07H0021-00 [ICM,7,C*]; C12N0009-00 [ICS,7];
 C12P0021-02 [ICS,7]; C12N0005-06 [ICS,7]
 IPCI-2 A61K0038-00 [I,A]
 IPCR C07H0021-00 [I,C*]; C07H0021-04 [I,A]; C12N0001-16 [I,C*];
 C12N0001-16 [I,A]; C12N0001-21 [I,C*]; C12N0001-21 [I,A];
 C12N0005-06 [I,C*]; C12N0005-06 [I,A]; C12N0005-16 [I,C*];
 C12N0005-16 [I,A]; C12N0009-00 [I,C*]; C12N0009-00 [I,A];
 C12N0015-12 [I,C*]; C12N0015-12 [I,A]; C12N0015-63 [I,C*];
 C12N0015-63 [I,A]; C12P0021-02 [I,C*]; C12P0021-02 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 16 OF 28 USPATFULL on STN
 AN 2003:37603 USPATFULL
 TI Human cDNAs and proteins and uses thereof
 IN Bejanin, Stephane, Paris, FRANCE
 Tanaka, Hiroaki, Antony, FRANCE
 PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
 PI US 20030027248 A1 20030206
 US 7074901 B2 20060711
 AI US 2001-924340 A1 20010806 (9)
 PRAI US 2001-305456P 20010713 (60)
 US 2001-302277P 20010629 (60)
 US 2001-298698P 20010615 (60)
 US 2001-293574P 20010525 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 25650
 INCL INCLM: 435/069.100
 INCLS: 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200;
 435/006.000
 NCL NCLM: 530/356.000; 435/069.100
 NCLS: 530/324.000; 435/006.000; 435/183.000; 435/320.100; 435/325.000;
 530/350.000; 536/023.200
 IC [7]
 ICM C12P021-02
 ICS C12Q001-68; C07H021-04; C12N009-00; C12N005-06
 IPCI C12P0021-02 [ICM,7]; C12Q0001-68 [ICS,7]; C07H0021-04 [ICS,7];
 C07H0021-00 [ICS,7,C*]; C12N0009-00 [ICS,7]; C12N0005-06 [ICS,7]
 IPCI-2 C07K0014-78 [I,A]; C07K0014-435 [I,C*]
 IPCR A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0048-00 [N,C*];
 A61K0048-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-47 [I,A];
 C07K0014-435 [I,C]; C07K0014-78 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 17 OF 28 USPATFULL on STN
 AN 2003:37516 USPATFULL
 TI Human cDNAs and proteins and uses thereof
 IN Bejanin, Stephane, Paris, FRANCE
 Tanaka, Hiroaki, Antony, FRANCE
 PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
 PI US 20030027161 A1 20030206
 US 7074571 B2 20060711
 AI US 2001-992600 A1 20011113 (9)
 RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
 PRAI WO 2001-IB1715 20010806
 US 2001-305456P 20010713 (60)
 US 2001-302277P 20010629 (60)
 US 2001-298698P 20010615 (60)
 US 2001-293574P 20010525 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 25529
 INCL INCLM: 435/006.000
 INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;
 536/023.200; 800/008.000
 NCL NCLM: 435/007.100; 435/006.000
 NCLS: 435/069.100; 435/071.100; 435/183.000; 435/212.000; 435/219.000;
 530/350.000; 530/412.000; 530/413.000; 435/320.100; 435/325.000;
 536/023.200; 800/008.000
 IC [7]
 ICM C12Q001-68
 ICS A01K067-00; C07H021-04; C12N009-00; C12P021-02; C12N005-06
 IPCI C12Q0001-68 [ICM,7]; A01K0067-00 [ICS,7]; C07H0021-04 [ICS,7];
 C07H0021-00 [ICS,7,C*]; C12N0009-00 [ICS,7]; C12P0021-02 [ICS,7];
 C12N0005-06 [ICS,7]
 IPCI-2 G01N0033-53 [I,A]; C07K0014-435 [I,A]; C12N0009-12 [I,A]
 IPCR A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0048-00 [N,C*];
 A61K0048-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-47 [I,A];
 G01N0033-53 [I,A]; C07K0014-435 [I,C]; C07K0014-435 [I,A];
 C12N0009-12 [I,C]; C12N0009-12 [I,A]; G01N0033-53 [I,C]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 18 OF 28 USPATFULL on STN
 AN 2002:108847 USPATFULL
 TI WISP polypeptides and nucleic acids encoding same
 IN Botstein, David A., Belmont, CA, United States
 Cohen, Robert L., San Mateo, CA, United States
 Goddard, Audrey D., San Francisco, CA, United States
 Gurney, Austin L., Belmont, CA, United States
 Hillan, Kenneth J., San Francisco, CA, United States
 Lawrence, David A., San Francisco, CA, United States
 Levine, Arnold J., New York, NY, United States
 Pennica, Diane, Burlingame, CA, United States
 Roy, Margaret Ann, San Francisco, CA, United States
 Wood, William I., Hillsborough, CA, United States
 PA Genentech, Inc., South San Francisco, CA, United States (U.S.
 corporation)
 PI US 6387657 B1 20020514
 AI US 1998-182145 19981029 (9)
 PRAI US 1997-63704P 19971029 (60)
 US 1998-73612P 19980204 (60)
 US 1998-81695P 19980414 (60)
 DT Utility
 FS GRANTED
 LN.CNT 5473

INCL INCLM: 435/069.100
 INCLS: 435/069.400; 435/325.000; 435/358.000; 435/243.000; 435/252.330;
 435/255.100; 435/320.100; 536/023.100; 536/023.500; 536/023.510

NCL NCLM: 435/069.100
 NCLS: 435/069.400; 435/243.000; 435/252.330; 435/255.100; 435/320.100;
 435/325.000; 435/358.000; 536/023.100; 536/023.500; 536/023.510

IC [7]
 ICM C12N015-12
 ICS C12N015-63; C12N001-21; C12N005-16; C12N001-16
 IPCI C12N0015-12 [ICM,7]; C12N0015-63 [ICS,7]; C12N0001-21 [ICS,7];
 C12N0005-16 [ICS,7]; C12N0001-16 [ICS,7]
 IPCR C07H0021-00 [I,C*]; C07H0021-04 [I,A]; C12N0001-16 [I,C*];
 C12N0001-16 [I,A]; C12N0001-21 [I,C*]; C12N0001-21 [I,A];
 C12N0005-06 [I,C*]; C12N0005-06 [I,A]; C12N0005-16 [I,C*];
 C12N0005-16 [I,A]; C12N0009-00 [I,C*]; C12N0009-00 [I,A];
 C12N0015-12 [I,C*]; C12N0015-12 [I,A]; C12N0015-63 [I,C*];
 C12N0015-63 [I,A]; C12P0021-02 [I,C*]; C12P0021-02 [I,A]

EXF 435/69.1; 435/69.4; 435/243; 435/320.1; 435/325; 435/358; 435/252.33;
 435/255.1; 536/23.1; 536/23.5; 536/23.51

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 19 OF 28 USPAT2 on STN
 AN 2005:30751 USPAT2
 TI β -Secretase variant
 IN Bejanin, Stephane, Paris, FRANCE
 Tanaka, Hiroaki, Antony, FRANCE
 PA Sero Genetics Institute S.A., Evry, FRANCE (non-U.S. corporation)
 PI US 7291495 B2 20071106
 AI US 2004-838854 20040503 (10)

RLI Division of Ser. No. US 2001-489, filed on 14 Nov 2001, Pat. No. US
 6794363 Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, Pat.
 No. US 7074901

PRAI WO 2001-IB1715 20010806
 US 2001-305456P 20010713 (60)
 US 2001-302277P 20010629 (60)
 US 2001-298698P 20010615 (60)
 US 2001-293574P 20010525 (60)

DT Utility
 FS GRANTED

LN.CNT 25533

INCL INCLM: 435/226.000
 INCLS: 435/320.100; 435/252.300; 435/252.330; 435/325.000; 435/254.100;
 435/070.100; 435/071.100

NCL NCLM: 435/226.000; 435/006.000
 NCLS: 435/070.100; 435/071.100; 435/252.300; 435/252.330; 435/254.100;
 435/320.100; 435/325.000; 435/069.100; 435/184.000; 536/023.200

IC IPCI C12Q0001-68 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*];
 C12N0009-99 [ICS,7]
 IPCI-2 C12N0009-64 [I,A]; C12N0015-63 [I,A]; C12N0001-20 [I,A];
 C12N0015-00 [I,A]; C12N0001-15 [I,A]; C12P0021-00 [I,A]
 IPCR C12N0009-64 [I,C]; C12N0009-64 [I,A]; A61K0038-00 [N,C*];
 A61K0038-00 [N,A]; A61K0048-00 [N,C*]; A61K0048-00 [N,A];
 C07K0014-435 [I,C*]; C07K0014-47 [I,A]; C12N0001-15 [I,C];
 C12N0001-15 [I,A]; C12N0001-20 [I,C]; C12N0001-20 [I,A];
 C12N0015-00 [I,C]; C12N0015-00 [I,A]; C12N0015-63 [I,C];
 C12N0015-63 [I,A]; C12P0021-00 [I,C]; C12P0021-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 20 OF 28 USPAT2 on STN
 AN 2003:282611 USPAT2
 TI Human cDNAs and proteins and uses thereof
 IN Bejanin, Stephane, Paris, FRANCE

Tanaka, Hiroaki, Antony, FRANCE
 PA Serono Genetics Institute SA, FRANCE (non-U.S. corporation)
 PI US 7122629 B2 20061017
 AI US 2001-1142 20011114 (10)
 RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
 PRAI WO 2001-1B1715 20010806
 US 2001-305456P 20010713 (60)
 US 2001-302277P 20010629 (60)
 US 2001-298698P 20010615 (60)
 US 2001-293574P 20010525 (60)
 DT Utility
 FS GRANTED
 LN.CNT 25455
 INCL INCLM: 530/350.000
 INCLS: 514/012.000; 435/007.100
 NCL NCLM: 530/350.000; 435/006.000
 NCLS: 435/007.100; 536/023.200
 IC IPCI C12Q0001-68 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*]
 IPCI-2 C07K0001-00 [I,A]; C07K0014-00 [I,A]; C07K0017-00 [I,A]
 IPCR C07K0001-00 [I,C]; C07K0001-00 [I,A]; A61K0038-00 [N,C*];
 A61K0038-00 [N,A]; A61K0048-00 [N,C*]; A61K0048-00 [N,A];
 C07K0014-00 [I,C]; C07K0014-00 [I,A]; C07K0014-435 [I,C*];
 C07K0014-47 [I,A]; C07K0017-00 [I,C]; C07K0017-00 [I,A]
 EXF 530/350; 514/12; 435/7.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 21 OF 28 USPAT2 on STN
 AN 2003:244219 USPAT2
 TI Human cDNAs and proteins and uses thereof
 IN Bejanin, Stephane, Paris, FRANCE
 Tanaka, Hiroaki, Antony, FRANCE
 PA Serono Genetics Institute SA, FRANCE (non-U.S. corporation)
 PI US 7094876 B2 20060822
 AI US 2001-999570 20011114 (9)
 RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
 PRAI WO 2001-1B1715 20010806
 US 2001-305456P 20010713 (60)
 US 2001-302277P 20010629 (60)
 US 2001-298698P 20010615 (60)
 US 2001-293574P 20010525 (60)
 DT Utility
 FS GRANTED
 LN.CNT 25345
 INCL INCLM: 530/350.000
 NCL NCLM: 530/350.000; 435/006.000
 NCLS: 435/007.100; 435/069.100; 435/320.100; 435/325.000; 530/388.100;
 536/023.500
 IC IPCI C12Q0001-68 [ICM,7]; G01N0033-53 [ICS,7]; C07H0021-04 [ICS,7];
 C07H0021-00 [ICS,7,C*]; C12P0021-02 [ICS,7]; C12N0005-06 [ICS,7];
 C07K0014-47 [ICS,7]; C07K0014-435 [ICS,7,C*]
 IPCI-2 C07K0001-00 [I,A]; C07K0014-00 [I,A]; C07K0017-00 [I,A]
 IPCR A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0048-00 [N,C*];
 A61K0048-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-47 [I,A]
 EXF 530/350; 514/12
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 22 OF 28 USPAT2 on STN
 AN 2003:231986 USPAT2
 TI Human cDNAs and proteins and uses thereof
 IN Bejanin, Stephane, Paris, FRANCE
 Tanaka, Hiroaki, Antony, FRANCE
 PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)

PI US 20070015144 A9 20070118
 AI US 2002-154678 A1 20020522 (10)
 RLI Continuation-in-part of Ser. No. US 2001-924340, filed on 6 Aug 2001,
 GRANTED, Pat. No. US 7074901
 PRAI US 2001-293574P 20010525 (60)
 US 2001-298698P 20010615 (60)
 US 2001-302277P 20010629 (60)
 US 2001-305456P 20010713 (60)
 US 2001-305456P 20010713 (60)
 US 2001-302277P 20010629 (60)
 US 2001-298698P 20010615 (60)
 US 2001-293574P 20010525 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 253/3
 INCL INCLM: 435/006.000
 INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200
 NCL NCLM: 435/006.000
 NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200
 IC IPCI C12Q0001-68 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*];
 C12N0009-00 [ICS,7]; C12P0021-02 [ICS,7]; C12N0005-06 [ICS,7]
 IPCI-2 C12Q0001-68 [I,A]; C07H0021-04 [I,A]; C07H0021-00 [I,C*];
 C12N0009-00 [I,A]; C12P0021-02 [I,A]; C12N0005-06 [I,A]
 IPCR C12Q0001-68 [I,C]; C12Q0001-68 [I,A]; A61K0038-00 [N,C*];
 A61K0038-00 [N,A]; A61K0048-00 [N,C*]; A61K0048-00 [N,A];
 C07H0021-00 [I,C]; C07H0021-04 [I,A]; C07K0014-435 [I,C*];
 C07K0014-47 [I,A]; C12N0005-06 [I,C]; C12N0005-06 [I,A];
 C12N0009-00 [I,C]; C12N0009-00 [I,A]; C12P0021-02 [I,C];
 C12P0021-02 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 23 OF 28 USPAT2 on STN
 AN 2003:225673 USPAT2
 TI Plasmin variants and uses thereof
 IN Bejanin, Stephane, Paris, FRANCE
 Tanaka, Hiroaki, Antony, FRANCE
 PA Sero Genetics Institute, S.A., FRANCE (non-U.S. corporation)
 PI US 6989262 B2 20060124
 AI US 2001-992095 20011113 (9)
 RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
 PRAI WO 2001-IB1715 20010806
 US 2001-305456P 20010713 (60)
 US 2001-302277P 20010629 (60)
 US 2001-298698P 20010615 (60)
 US 2001-293574P 20010525 (60)
 DT Utility
 FS GRANTED
 LN.CNT 253/6
 INCL INCLM: 435/226.000
 INCLS: 435/252.300; 435/041.000; 435/068.100; 424/094.640
 NCL NCLM: 435/226.000; 435/006.000
 NCLS: 424/094.640; 435/041.000; 435/068.100; 435/252.300; 435/007.200;
 435/069.100; 435/320.100; 435/325.000; 530/388.260; 536/023.200;
 800/008.000
 IC IPCI C12Q0001-68 [ICM,7]; G01N0033-53 [ICS,7]; G01N0033-567 [ICS,7];
 A01K0067-00 [ICS,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*];
 C12N0009-64 [ICS,7]; C12P0021-02 [ICS,7]; C12N0005-06 [ICS,7]
 IPCI-2 C12N0009-64 [I,A]; C12N0001-20 [I,A]; C12P0001-00 [I,A];
 C12P0021-06 [I,A]; A61K0038-48 [I,A]; A61K0038-43 [I,C*]
 IPCR A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0048-00 [N,C*];
 A61K0048-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-47 [I,A];
 C12N0009-64 [I,A]; A61K0038-43 [I,C]; A61K0038-43 [I,A];

C12N0001-20 [I,C]; C12N0001-20 [I,A]; C12N0009-64 [I,C];
 C12P0001-00 [I,C]; C12P0001-00 [I,A]; C12P0021-06 [I,C];
 C12P0021-06 [I,A]
 EXF 435/226; 435/252.3; 435/41; 435/68.1; 424/94.64; 536/23.2
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 24 OF 28 USPAT2 on STN
 AN 2003:140406 USPAT2
 TI Human cDNAs and proteins and uses thereof
 IN Bejanin, Stephane, Paris, FRANCE
 Tanaka, Hiroaki, Antony, FRANCE
 PA Serozo Genetics Institute, Inc., FRANCE (non-U.S. corporation)
 PI US 7005500 B2 20060228
 AI US 2001-986 20011114 (10)
 RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
 PRAI WO 2001-IB1715 20010806
 US 2001-305456P 20010713 (60)
 US 2001-302277P 20010629 (60)
 US 2001-298698P 20010615 (60)
 US 2001-293574P 20010525 (60)
 DT Utility
 FS GRANTED
 LN.CNT 25585
 INCL INCLM: 530/350.000
 NCL NCLM: 530/350.000; 435/006.000
 NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200;
 800/008.000
 IC IPCI C12Q0001-68 [ICM,7]; A01K0067-00 [ICS,7]; C07H0021-04 [ICS,7];
 C07H0021-00 [ICS,7,C*]; C12N0009-00 [ICS,7]; C12P0021-02 [ICS,7];
 C12N0005-06 [ICS,7]
 IPCI-2 A61K0038-00 [I,A]
 IPCR A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0048-00 [N,C*];
 A61K0048-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-47 [I,A];
 A61K0038-00 [I,A]; A61K0038-00 [I,C]
 EXF 530/350
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 25 OF 28 USPAT2 on STN
 AN 2003:133926 USPAT2
 TI Isolated amyloid inhibitor protein (APIP) and compositions thereof
 IN Bejanin, Stephane, Paris, FRANCE
 Tanaka, Hiroaki, Antony, FRANCE
 PA Genset S.A., FRANCE (non-U.S. corporation)
 PI US 6794363 B2 20040921
 AI US 2001-489 20011114 (10)
 RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001
 PRAI US 2001-305456P 20010713 (60)
 US 2001-302277P 20010629 (60)
 US 2001-298698P 20010615 (60)
 US 2001-293574P 20010525 (60)
 DT Utility
 FS GRANTED
 LN.CNT 25550
 INCL INCLM: 514/012.000
 INCLS: 530/350.000; 536/023.500; 435/023.000
 NCL NCLM: 514/012.000; 435/006.000
 NCLS: 435/023.000; 530/350.000; 536/023.500; 435/007.900; 435/069.100;
 435/183.000; 435/320.100; 435/325.000; 536/023.200; 800/003.000
 IC [7]
 ICM C12Q0001-37
 ICS C07H021-04; C07K014-00; A61K038-00
 IPCI C12Q0001-68 [ICM,7]; G01N0033-53 [ICS,7]; G01N0033-542 [ICS,7];

G01N0033-536 [ICS,7,C*]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*]; C12N0009-00 [ICS,7]; C12P0021-02 [ICS,7]; C12N0005-06 [ICS,7]
 IPCI-2 C12Q0001-37 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*]; C07K0014-00 [ICS,7]; A61K0038-00 [ICS,7]
 IPCR A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0048-00 [N,C*]; A61K0048-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-47 [I,A]
 EXF 435/23; 530/350; 536/23.5; 514/12
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 26 OF 28 USPAT2 on STN
 AN 2003:99573 USPAT2
 TI WISP polypeptides and nucleic acids encoding same
 IN Levine, Arnold J., New York, NY, UNITED STATES
 Pennica, Diane, Burlingame, CA, UNITED STATES
 PA Genentech, Inc., South San Francisco, CA, UNITED STATES (U.S. corporation)
 PI US 7101850 B2 20060905
 AI US 2002-112267 20020327 (10)
 RLI Division of Ser. No. US 1998-182145, filed on 29 Oct 1998, Pat. No. US 6387657
 PRAI US 1998-81695P 19980414 (60)
 US 1998-73612P 19980204 (60)
 US 1997-63704P 19971029 (60)
 DT Utility
 FS GRANTED
 LN.CNT 9667
 INCL INCLM: 514/012.000
 INCLS: 530/350.000
 NCL NCLM: 514/012.000; 435/069.100
 NCLS: 530/350.000; 435/183.000; 435/320.100; 435/325.000; 536/023.500
 IC IPCI C07H0021-04 [ICM,7]; C07H0021-00 [ICM,7,C*]; C12N0009-00 [ICS,7]; C12P0021-02 [ICS,7]; C12N0005-06 [ICS,7]
 IPCI-2 A61K0038-00 [I,A]
 IPCR C07H0021-00 [I,C*]; C07H0021-04 [I,A]; C12N0001-16 [I,C*]; C12N0001-16 [I,A]; C12N0001-21 [I,C*]; C12N0001-21 [I,A]; C12N0005-06 [I,C*]; C12N0005-06 [I,A]; C12N0005-16 [I,C*]; C12N0005-16 [I,A]; C12N0009-00 [I,C*]; C12N0009-00 [I,A]; C12N0015-12 [I,C*]; C12N0015-12 [I,A]; C12N0015-63 [I,C*]; C12N0015-63 [I,A]; C12P0021-02 [I,C*]; C12P0021-02 [I,A]
 EXF 424/198.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 27 OF 28 USPAT2 on STN
 AN 2003:37603 USPAT2
 TI Isolated human vCOL16A1 polypeptide and fragments thereof
 IN Bejanin, Stephane, Paris, FRANCE
 Tanaka, Hiroaki, Antony, FRANCE
 PA Serono Genetics Institute S.A., Evry, FRANCE (non-U.S. corporation)
 PI US 7074901 B2 20060711
 AI US 2001-924340 20010806 (9)
 PRAI US 2001-305456P 20010713 (60)
 US 2001-302277P 20010629 (60)
 US 2001-298698P 20010615 (60)
 US 2001-293574P 20010525 (60)
 DT Utility
 FS GRANTED
 LN.CNT 25381
 INCL INCLM: 530/356.000
 INCLS: 530/324.000
 NCL NCLM: 530/356.000; 435/069.100
 NCLS: 530/324.000; 435/006.000; 435/183.000; 435/320.100; 435/325.000;

530/350.000; 536/023.200

IC IPCI C12P0021-02 [ICM,7]; C12Q0001-68 [ICS,7]; C07H0021-04 [ICS,7];
C07H0021-00 [ICS,7,C*]; C12N0009-00 [ICS,7]; C12N0005-06 [ICS,7]
IPCI-2 C07K0014-78 [I,A]; C07K0014-435 [I,C*]
IPCR A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0048-00 [N,C*];
A61K0048-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-47 [I,A];
C07K0014-435 [I,C]; C07K0014-78 [I,A]

EXF 530/350

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 28 OF 28 USPAT2 on STN

AN 2003:37516 USPAT2

TI Serine carboxypeptidase hx (SCPhx) and compositions thereof

IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE

PA Serono Genetics Institute SA, FRANCE (non-U.S. corporation)

PI US 7074571 B2 20060711

AI US 2001-992600 20011113 (9)

RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING

PRAI WO 2001-1B1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)

DT Utility

FS GRANTED

LN.CNT 25479

INCL INCLM: 435/007.100
INCLS: 435/069.100; 435/071.100; 435/183.000; 435/212.000; 435/219.000;
530/350.000; 530/412.000; 530/413.000

NCL NCLM: 435/007.100; 435/006.000
NCLS: 435/069.100; 435/071.100; 435/183.000; 435/212.000; 435/219.000;
530/350.000; 530/412.000; 530/413.000; 435/320.100; 435/325.000;
536/023.200; 800/008.000

IC IPCI C12Q0001-68 [ICM,7]; A01K0067-00 [ICS,7]; C07H0021-04 [ICS,7];
C07H0021-00 [ICS,7,C*]; C12N0009-00 [ICS,7]; C12P0021-02 [ICS,7];
C12N0005-06 [ICS,7]
IPCI-2 G01N0033-53 [I,A]; C07K0014-435 [I,A]; C12N0009-12 [I,A]
IPCR A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0048-00 [N,C*];
A61K0048-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-47 [I,A];
G01N0033-53 [I,A]; C07K0014-435 [I,C]; C07K0014-435 [I,A];
C12N0009-12 [I,C]; C12N0009-12 [I,A]; G01N0033-53 [I,C]

EXF 530/350; 530/323; 530/324; 530/325; 530/326; 530/327; 530/328; 530/329;
530/330; 435/183; 435/212; 435/219

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s osteoblast produc? and lactoperoxidase

11 FILES SEARCHED...

L10 1 OSTEOBLAST PRODUC? AND LACTOPEROXIDASE

=> d 110 1

L10 ANSWER 1 OF 1 USPATFULL on STN

AN 2007:23595 USPATFULL

TI Full-length cDNA

IN Isogai, Takao, Ibaraki, JAPAN
Sugiyama, Tomoyasu, Tokyo, JAPAN
Otsuki, Tetsuji, Tokyo, JAPAN
Wakamatsu, Al, Chiba, JAPAN
Sato, Hiroyuki, Osaka, JAPAN
Ishii, Shizuko, Hokkaido, JAPAN

Yamamoto, Junichi, Chiba, JAPAN
 Isono, Yuko, Chiba, JAPAN
 Nagai, Keiichi, Tokyo, JAPAN
 Irie, Ryotaro, Saitama, JAPAN
 PA RESEARCH ASSOCIATION FOR BIOTECHNOLOGY (non-U.S. corporation)
 PI US 20070020637 A1 20070125
 AI US 2004-760320 A1 20040121 (10)
 PRAI JP 2003-102206 20030121
 JP 2003-131392 20030509
 US 2003-476227P 20030606 (60)
 US 2003-447287P 20030214 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 117230
 INCL INCLM: 435/006.000
 INCLS: 536/023.100
 NCL NCLM: 435/006.000
 NCLS: 536/023.100
 IC IPCI C12Q0001-68 [I,A]; C07H0021-04 [I,A]; C07H0021-00 [I,C*]
 IPCR C12Q0001-68 [I,C]; C12Q0001-68 [I,A]; C07H0021-00 [I,C];
 C07H0021-04 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l10 1 ab

L10 ANSWER 1 OF 1 USPATFULL on STN
 AB Novel full-length cDNAs are provided. 2,495 cDNA derived from human have been isolated. The full-length nucleotide sequences of the cDNA and amino acid sequences encoded by the nucleotide sequences have been determined. Because the cDNA of the present invention are full-length and contain the translation start site, they provide information useful for analyzing the functions of the polypeptide.

=> file uspatfull
 COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
79.77	82.58

FULL ESTIMATED COST

FILE 'USPATFULL' ENTERED AT 21:01:45 ON 20 JUN 2008
 CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 19 Jun 2008 (20080619/PD)
 FILE LAST UPDATED: 19 Jun 2008 (20080619/ED)
 HIGHEST GRANTED PATENT NUMBER: US7389542
 HIGHEST APPLICATION PUBLICATION NUMBER: US20080148460
 CA INDEXING IS CURRENT THROUGH 19 Jun 2008 (20080619/UFGA)
 ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 19 Jun 2008 (20080619/PD)
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2008
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2008

=> s lactoperoxidase in food
 2700 LACTOPEROXIDASE
 244599 FOOD

L11 0 LACTOPEROXIDASE IN FOOD
 (LACTOPEROXIDASE(1W)FOOD)

=> s food containing lactoperoxidase
 244599 FOOD
 2059046 CONTAINING

2700 LACTOPEROXIDASE
 L12 0 FOOD CONTAINING LACTOPEROXIDASE
 (FOOD(W)CONTAINING(W)LACTOPEROXIDASE)

 => s food and lactoperoxidase
 244599 FOOD
 2700 LACTOPEROXIDASE
 L13 707 FOOD AND LACTOPEROXIDASE

 => s l13 and (drink or feed)
 28894 DRINK
 573082 FEED
 L14 191 L13 AND (DRINK OR FEED)

 => s l14 and contain?(p)lactoperoxidase
 3069451 CONTAIN?
 2700 LACTOPEROXIDASE
 831 CONTAIN?(P)LACTOPEROXIDASE
 L15 88 L14 AND CONTAIN?(P)LACTOPEROXIDASE

 => s l15 and bone
 137746 BONE
 L16 14 L15 AND BONE

 => d l16 1-14

 L16 ANSWER 1 OF 14 USPATFULL on STN
 AN 2008:158939 USPATFULL
 TI Compositions and methods for treatment of cancer
 IN de Sauvage, Fred, Foster City, CA, UNITED STATES
 Goddard, Audrey, San Francisco, CA, UNITED STATES
 Gurney, Austin L., Belmont, CA, UNITED STATES
 Hongo, Jo-Anne, Redwood City, CA, UNITED STATES
 Smith, Victoria, Burlingame, CA, UNITED STATES
 PA Genentech, Inc. (U.S. corporation)
 PI US 20080138345 A1 20080612
 AI US 2005-120399 A1 20050502 (11)
 RLI Continuation of Ser. No. US 2001-769087, filed on 24 Jan 2001, ABANDONED
 PRAI US 2000-177951P 20000125 (60)
 US 2000-195761P 20000410 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 5318
 INCL INCLM: 424/139.100
 INCLS: 530/387.900; 435/331.000; 435/072.300; 424/178.100; 530/387.300;
 435/252.800; 435/255.100
 NCL NCLM: 424/139.100
 NCLS: 530/387.900; 435/331.000; 435/072.300; 424/178.100; 530/387.300;
 435/252.800; 435/255.100
 IC IPCI A61K0039-395 [I,A]; C07K0016-00 [I,A]; C12N0005-00 [I,A];
 C12N0005-06 [I,A]; C12N0001-16 [I,A]; C12N0001-20 [I,A];
 A61P0035-04 [I,A]; A61P0035-00 [I,C*]; G01N0033-574 [I,A]

 L16 ANSWER 2 OF 14 USPATFULL on STN
 AN 2008:50792 USPATFULL
 TI MILK PROTEIN ISOLATE AND PROCESS FOR ITS PREPARATION
 IN Soupe, Jerome, Rennes, FRANCE
 PA Compagnie Laitiere Europeene (non-U.S. corporation)
 PI US 20080044544 A1 20080221
 AI US 2007-757485 A1 20070604 (11)
 RLI Continuation of Ser. No. US 2005-519131, filed on 4 Aug 2005, GRANTED,
 Pat. No. US 7247331 A 371 of International Ser. No. WO 2003-FR2015,

filed on 30 Jun 2003
 PRAI FR 2002-8234 20020702
 DT Utility
 FS APPLICATION
 LN.CNT 605
 INCL INCLM: 426/580.000
 NCL NCLM: 426/580.000
 IC IPCI A23C0009-00 [I,A]
 IPCR A23C0009-00 [I,C]; A23C0009-00 [I,A]; A23C0009-146 [I,A];
 A23J0001-00 [I,C*]; A23J0001-20 [I,A]; A23L0001-305 [I,C*];
 A23L0001-305 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A];
 A61K0038-40 [I,C*]; A61K0038-40 [I,A]; A61P0019-00 [I,C*];
 A61P0019-00 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 3 OF 14 USPATFULL on STN
 AN 2007:302272 USPATFULL
 TI COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
 IN de Sauvage, Frederic, Foster City, CA, UNITED STATES
 Goddard, Audrey, San Francisco, CA, UNITED STATES
 Gurney, Austin L., Belmont, CA, UNITED STATES
 Hongo, Jo-Anne S., Redwood City, CA, UNITED STATES
 Smith, Victoria, Burlingame, CA, UNITED STATES
 PA Genentech, Inc., South San Francisco, CA, UNITED STATES (U.S.
 corporation)
 PI US 20070264267 A1 20071115
 AI US 2006-538881 A1 20061005 (11)
 RLI Continuation of Ser. No. US 2002-182033, filed on 24 Oct 2002, PENDING A
 371 of International Ser. No. WO 2001-US2622, filed on 25 Jan 2001
 PRAI US 2000-177951P 20000125 (60)
 US 2000-195761P 20000410 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 5472
 INCL INCLM: 424/183.100
 INCLS: 435/252.330; 435/254.200; 435/346.000; 435/348.000; 435/358.000;
 435/006.000; 435/007.920; 530/324.000; 530/391.700; 536/023.100
 NCL NCLM: 424/183.100
 NCLS: 435/006.000; 435/007.920; 435/252.330; 435/254.200; 435/346.000;
 435/348.000; 435/358.000; 530/324.000; 530/391.700; 536/023.100
 IC IPCI A61K0039-395 [I,A]; A61P0035-00 [I,A]; C07H0021-04 [I,A];
 C07H0021-00 [I,C*]; C07K0014-00 [I,A]; C07K0016-00 [I,A];
 C12N0001-19 [I,A]; C12N0001-21 [I,A]; C12N0005-10 [I,A];
 C12N0005-12 [I,A]; C12Q0001-68 [I,A]; G01N0033-574 [I,A]
 IPCR A61K0039-395 [I,C]; A61K0039-395 [I,A]; A61P0035-00 [I,C];
 A61P0035-00 [I,A]; C07H0021-00 [I,C]; C07H0021-04 [I,A];
 C07K0014-00 [I,C]; C07K0014-00 [I,A]; C07K0014-435 [I,C*];
 C07K0014-47 [I,A]; C07K0016-00 [I,C]; C07K0016-00 [I,A];
 C07K0016-18 [I,C*]; C07K0016-30 [I,A]; C12N0001-19 [I,C];
 C12N0001-19 [I,A]; C12N0001-21 [I,C]; C12N0001-21 [I,A];
 C12N0005-10 [I,C]; C12N0005-10 [I,A]; C12N0005-12 [I,C];
 C12N0005-12 [I,A]; C12Q0001-68 [I,C]; C12Q0001-68 [I,A];
 G01N0033-574 [I,C]; G01N0033-574 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 4 OF 14 USPATFULL on STN
 AN 2007:290246 USPATFULL
 TI Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof
 IN Naidu, A. Satyanarayan, Diamond Bar, CA, UNITED STATES
 Naidu, A.G. Tezus, Diamond Bar, CA, UNITED STATES
 Naidu, A.G. Sreus, Diamond Bar, CA, UNITED STATES
 PI US 20070253941 A1 20071101

AI US 2006-482653 A1 20060707 (11)
 PRAI US 2006-795871P 20060428 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2445
 INCL INCLM: 424/094.100
 INCLS: 514 6; 514/690.000
 NCL NCLM: 424/094.100
 NCLS: 514/006.000; 514/690.000
 IC IPCI A61K0038-43 [I,A]; A61K0038-40 [I,A]; A61K0031-12 [I,A]
 IPCR A61K0038-43 [I,C]; A61K0038-43 [I,A]; A61K0031-12 [I,C];
 A61K0031-12 [I,A]; A61K0038-40 [I,C]; A61K0038-40 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 5 OF 14 USPATFULL on SIN
 AN 2006;267664 USPATFULL
 TI Osteogenesis promoter
 IN Motouri, Mutsumi, Saitama, JAPAN
 Matsuyama, Hiroaki, Saitama, JAPAN
 Morita, Yoshikazu, Saitami, JAPAN
 Serizawa, Atsushi, Saitama, JAPAN
 Kawakami, Hiroshi, Saitama, JAPAN
 PI US 20060228345 A1 20061012
 AI US 2004-566711 A1 20040813 (10)
 WO 2004-JP11689 20040813
 20060315 PCT 371 date
 PRAI JP 2003-293829 20030815
 DT Utility
 FS APPLICATION
 LN.CNT 420
 INCL INCLM: 424/094.400
 INCLS: 424/439.000
 NCL NCLM: 424/094.400
 NCLS: 424/439.000
 IC IPCI A61K0038-44 [I,A]; A61K0038-43 [I,C*]; A61K0047-00 [I,A]
 IPCR A61K0038-43 [I,C]; A61K0038-44 [I,A]; A23K0001-165 [I,C*];
 A23K0001-165 [I,A]; A23L0001-30 [I,C*]; A23L0001-30 [I,A];
 A23L0001-305 [I,C*]; A23L0001-305 [I,A]; A61K0035-20 [I,C*];
 A61K0035-20 [I,A]; A61K0038-00 [I,C*]; A61K0038-00 [I,A];
 A61K0047-00 [I,C]; A61K0047-00 [I,A]; A61P0019-00 [I,C*];
 A61P0019-00 [I,A]; A61P0019-08 [I,A]; A61P0019-10 [I,A];
 A61P0043-00 [I,C*]; A61P0043-00 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 6 OF 14 USPATFULL on SIN
 AN 2006;46555 USPATFULL
 TI Milk protein isolate and method for preparing same
 IN Souppe, Jerome, Rennes, FRANCE
 PI US 20060040025 A1 20060223
 US 7247331 B2 20070724
 AI US 2003-519131 A1 20030630 (10)
 WO 2003-FR2015 20030630
 20050804 PCT 371 date
 PRAI FR 2002-8234 20020702
 DT Utility
 FS APPLICATION
 LN.CNT 707
 INCL INCLM: 426/490.000
 INCLS: 426/580.000
 NCL NCLM: 426/491.000; 426/490.000
 NCLS: 426/271.000; 426/580.000; 426/587.000; 426/588.000; 426/590.000;
 514/775.000; 530/416.000

IC IPCI C12G0003-08 [I,A]; C12G0003-00 [I,C*]
 IPCI-2 A23C0001-00 [I,A]; A23J0001-20 [I,A]; A23J0001-00 [I,C*];
 A23L0002-38 [I,A]; A61K0047-00 [I,A]; C07K0001-18 [I,A];
 C07K0001-00 [I,C*]
 IPCR A23C0001-00 [I,C]; A23C0001-00 [I,A]; A23C0009-00 [I,C*];
 A23C0009-146 [I,A]; A23J0001-00 [I,C]; A23J0001-20 [I,A];
 A23L0001-305 [I,C*]; A23L0001-305 [I,A]; A23L0002-38 [I,C];
 A23L0002-38 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A];
 A61K0038-40 [I,C*]; A61K0038-40 [I,A]; A61K0047-00 [I,C];
 A61K0047-00 [I,A]; A61P0019-00 [I,C*]; A61P0019-00 [I,A];
 C07K0001-00 [I,C]; C07K0001-18 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 7 OF 14 USPATFULL on SIN
 AN 2005:298585 USPATFULL
 TI Medicinal products incorporating bound organosulfur groups
 IN Ott, David M., Oakland, CA, UNITED STATES
 PI US 20050260250 A1 20051124
 AI US 2005-137747 A1 20050524 (11)
 PRAI US 2004-574374P 20040524 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3695
 INCL INCLM: 424/439.000
 INCLS: 514/012.000; 424/754.000
 NCL NCLM: 424/439.000
 NCLS: 424/754.000; 514/012.000

IC [7]
 ICM A61K035-78
 ICS A61K038-16; A61K047-00
 IPCI A61K0035-78 [ICM,7]; A61K0038-16 [ICS,7]; A61K0047-00 [ICS,7]
 IPCR A23L0001-221 [I,C*]; A23L0001-221 [I,A]; A23L0001-30 [I,C*];
 A23L0001-30 [I,A]; A23L0001-305 [I,C*]; A23L0001-305 [I,A];
 A61K0036-88 [I,C*]; A61K0036-8962 [I,A]; A61K0038-16 [I,C*];
 A61K0038-16 [I,A]; A61K0047-00 [I,C*]; A61K0047-00 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 8 OF 14 USPATFULL on SIN
 AN 2005:98544 USPATFULL
 TI Filters for preventing or reducing tobacco smoke-associated injury in
 the aerodigestive tract of a subject
 IN Reznick, Abraham Z., Nofit, ISRAEL
 Nagler, Rafael M., Timrat, ISRAEL
 Klein, Ifat, Doar Na Galil Elion, ISRAEL
 PI US 20050084459 A1 20050421
 AI US 2004-931213 A1 20040901 (10)
 RLI Division of Ser. No. US 2001-987688, filed on 15 Nov 2001, GRANTED, Pat.
 No. US 6789546
 PRAI US 2001-304402P 20010712 (60)
 US 2001-300443P 20010626 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1648
 INCL INCLM: 424/048.000
 INCLS: 424/049.000; 424/058.000
 NCL NCLM: 424/048.000
 NCLS: 424/049.000; 424/058.000
 IC [7]
 ICM A61K009-68
 ICS A61K007-16; A61K007-26
 IPCI A61K0009-68 [ICM,7]; A61K0007-16 [ICS,7]; A61K0007-26 [ICS,7]
 IPCR A61K0031-7135 [I,C*]; A61K0031-714 [I,A]

L16 ANSWER 9 OF 14 USPATFULL on STN
AN 2004:146090 USPATFULL
TI Expression of human milk proteins in transgenic plants
IN Huang, Ning, Davis, CA, UNITED STATES
Rodriguez, Raymond L., Davis, CA, UNITED STATES
Hagie, Frank E., Sacramento, CA, UNITED STATES
PA Ventria Bioscience (U.S. corporation)
PI US 20040111766 A1 20040610
AI US 2003-639835 A1 20030812 (10)
RLI Continuation-in-part of Ser. No. US 2002-77381, filed on 14 Feb 2002,
PENDING Continuation-in-part of Ser. No. US 2001-847232, filed on 2 May
2001, PENDING
PRAI US 2001-269199P 20010214 (60)
US 2001-266929P 20010206 (60)
US 2000-201182P 20000502 (60)
DT Utility
FS APPLICATION
LN.CNT 5337
INCL INCLM: 800/288.000
INCLS: 800/320.200; 800/320.300
NCL NCLM: 800/288.000
NCLS: 800/320.200; 800/320.300
IC [7]
ICM A01H001-00
ICS C12N015-82; A01H005-00
IPC1 A01H0001-00 [ICM,7]; C12N0015-82 [ICS,7]; A01H0005-00 [ICS,7]
IPC2 A23K0001-14 [I,C*]; A23K0001-14 [I,A]; A23K0001-16 [I,C*];
A23K0001-16 [I,A]; A23L0001-10 [I,C*]; A23L0001-10 [I,A];
A23L0001-185 [I,C*]; A23L0001-185 [I,A]; A23L0001-30 [I,C*];
A23L0001-30 [I,A]; A23L0001-305 [I,C*]; A23L0001-305 [I,A];
C07K0014-415 [I,C*]; C07K0014-415 [I,A]; C07K0014-435 [I,C*];
C07K0014-485 [I,A]; C07K0014-65 [I,A]; C07K0014-79 [I,A];
C07K0014-81 [I,C*]; C07K0014-81 [I,A]; C12N0009-08 [I,C*];
C12N0009-08 [I,A]; C12N0009-36 [I,C*]; C12N0009-36 [I,A];
C12N0015-82 [I,C*]; C12N0015-82 [I,A]; G01N0033-574 [I,C*];
G01N0033-574 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 10 OF 14 USPATFULL on STN
AN 2003:306025 USPATFULL
TI Compositions and methods for treatment of cancer
IN Sauvage, Frederic de, Foster City, CA, UNITED STATES
Goddard, Audrey, San Francisco, CA, UNITED STATES
Gurney, Austin L., Belmont, CA, UNITED STATES
Hongo, Jo-Anne S., Redwood City, CA, UNITED STATES
PI US 20030215457 A1 20031120
US 7285382 B2 20071023
AI US 2002-182033 A1 20021024 (10)
WO 2001-US2622 20010125
DT Utility
FS APPLICATION
LN.CNT 5446
INCL INCLM: 424/185.100
INCLS: 435/069.300; 435/320.100; 435/325.000; 530/350.000; 530/388.800;
435/007.230
NCL NCLM: 435/005.000; 424/185.100
NCLS: 435/007.230; 435/069.300; 435/320.100; 435/325.000; 530/350.000;
530/388.800
IC [7]
ICM G01N033-574
ICS C07K014-47; C12P021-02; C12N005-06; C07K016-18

IPCI G01N0033-574 [ICM,7]; C07K0014-47 [ICS,7]; C07K0014-435
[ICS,7,C*]; C12P0021-02 [ICS,7]; C12N0005-06 [ICS,7]; C07K0016-18
[ICS,7]
IPCI-2 C12Q0001-70 [I,A]
IPCR C12Q0001-70 [I,C]; C12Q0001-70 [I,A]; C07K0014-435 [I,C*];
C07K0014-47 [I,A]; C07K0016-18 [I,C*]; C07K0016-30 [I,A];
G01N0033-574 [I,C*]; G01N0033-574 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 11 OF 14 USPATFULL on STN
AN 2003:172818 USPATFULL
TI Therapeutic uses of milk mineral fortified food products
IN Bastian, Eric Douglas, Twin Falls, ID, UNITED STATES
Ward, Loren Spencer, Twin Falls, ID, UNITED STATES
PA Glanbia Foods, Inc., Twin Falls, ID, UNITED STATES (U.S. corporation)
PI US 20030118662 A1 20030626
AI US 2001-2011 A1 20011205 (10)
DT Utility
FS APPLICATION
LN.CNT 444
INCL INCLM: 424/535.000
NCL NCLM: 424/535.000
IC [7]
ICM A61K035-20
IPCI A61K0035-20 [ICM,7]
IPCR A21D0002-00 [I,C*]; A21D0002-02 [I,A]; A23C0009-13 [I,C*];
A23C0009-13 [I,A]; A23C0009-133 [I,A]; A23G0003-00 [I,C*];
A23G0003-00 [I,A]; A23G0003-34 [I,C*]; A23G0003-36 [I,A];
A23G0003-46 [I,A]; A23L0001-304 [I,C*]; A23L0001-304 [I,A];
A23L0002-02 [I,C*]; A23L0002-02 [I,A]; A23L0002-52 [I,C*];
A23L0002-52 [I,A]; A61K0035-20 [I,C*]; A61K0035-20 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 12 OF 14 USPATFULL on STN
AN 2003:95803 USPATFULL
TI Periodontal disease preventive and ameliorative agent
IN Takada, Yukihiro, Kawagoe, JAPAN
Aoe, Seiichirou, Sayama, JAPAN
Serizawa, Atsusi, Kawagoe, JAPAN
Suguri, Toshiaki, Tokyo, JAPAN
Dousako, Shunichi, Urawa, JAPAN
PA Snow Brand Milk Products Co., Ltd., Hokkai-do, JAPAN (non-U.S.
corporation)
PI US 6544498 B1 20030408
WO 9956762 19991111
AI US 2000-446279 20000320 (9)
WO 1999-JP2223 19990427
PRAI JP 1998-134243 19980430
DT Utility
FS GRANTED
LN.CNT 245
INCL INCLM: 424/049.000
INCLS: 514/012.000; 514/016.000; 514/021.000; 514/900.000; 514/901.000
NCL NCLM: 424/049.000
NCLS: 514/012.000; 514/016.000; 514/021.000; 514/900.000; 514/901.000
IC [7]
ICM A61K007-16
ICS A61K038-00
IPCI A61K0007-16 [ICM,7]; A61K0038-00 [ICS,7]
IPCR A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A23G0004-00 [I,C*];
A23G0004-00 [I,A]; A23J0003-00 [I,C*]; A23J0003-00 [I,A];
A23L0001-305 [I,C*]; A23L0001-305 [I,A]; A61K0008-30 [I,C*];

A61K0008-64 [I,A]; A61K0035-20 [I,C*]; A61K0035-20 [I,A];
 A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61K0038-01 [I,C*];
 A61K0038-01 [I,A]; A61K0038-02 [I,C*]; A61K0038-02 [I,A];
 A61K0038-17 [I,C*]; A61K0038-17 [I,A]; A61P0001-00 [I,C*];
 A61P0001-02 [I,A]; A61Q0011-00 [I,C*]; A61Q0011-00 [I,A];
 A23G0004-06 [I,C*]; A23G0004-12 [I,A]; A23G0004-14 [I,A];
 A23G0004-16 [I,A]

EXF 514/12; 514/16; 514/21

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 13 OF 14 USPATFULL on STN

AN 2003:80313 USPATFULL

TI Feed additive compositions and methods

IN Huang, Ning, Davis, CA, UNITED STATES
 Rodriguez, Raymond L., Davis, CA, UNITED STATES
 Hagie, Frank E., Sacramento, CA, UNITED STATES

PI US 20030056244 A1 20030320

AI US 2002-76816 A1 20020214 (10)

RLI Continuation-in-part of Ser. No. US 2001-847232, filed on 2 May 2001,
 PENDING

PRAI WO 2001-US14234 20011108

US 2001-269188P 20010214 (60)

US 2001-266929P 20010206 (60)

US 2000-201182P 20000502 (60)

DT Utility

FS APPLICATION

LN.CNT 5847

INCL INCLM: 800/278.000

INCLS: 424/442.000; 426/053.000

NCL NCLM: 800/278.000

NCLS: 424/442.000; 426/053.000

IC [7]

ICM A23K001-165

ICS A23K001-17

IPCI A23K0001-165 [ICM,7]; A23K0001-17 [ICS,7]

IPCR A23K0001-14 [I,C*]; A23K0001-14 [I,A]; A23K0001-16 [I,C*];
 A23K0001-16 [I,A]; A23L0001-185 [I,C*]; A23L0001-185 [I,A];
 A23L0001-30 [I,C*]; A23L0001-30 [I,A]; A23L0001-305 [I,C*];
 A23L0001-305 [I,A]; C07K0014-415 [I,C*]; C07K0014-415 [I,A];
 C07K0014-435 [I,C*]; C07K0014-485 [I,A]; C07K0014-65 [I,A];
 C07K0014-79 [I,A]; C07K0014-81 [I,C*]; C07K0014-81 [I,A];
 C12N0009-08 [I,C*]; C12N0009-08 [I,A]; C12N0009-36 [I,C*];
 C12N0009-36 [I,A]; C12N0015-82 [I,C*]; C12N0015-82 [I,A];
 G01N0033-574 [I,C*]; G01N0033-574 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 14 OF 14 USPATFULL on STN

AN 1999:88838 USPATFULL

TI Bone reinforcing agent and foods and drinks product containing
 the same

IN Kato, Ken, 11-3, Arajuku-cho 5-chome, Kawagoe, Japan
 Matsuyama, Hiroaki, 11-3, Arajuku-cho 5-chome, Kawagoe, Japan
 Takada, Yukihiko, 62-22, Kozutsumi, Kawagoe, Japan
 Uchida, Toshiaki, 11-3, Arajuku-cho 5-chome, Kawagoe, Japan
 Aoe, Seiichiro, 8-9-406 Shinsayama 2-chome, Satana, Japan

PI US 5932259 19990803

AI US 1995-532399 19950922 (8)

PRAI JP 1994-261609 19940930

JP 1995-207509 19950721

DT Utility

FS Granted

LN.CNT 459

INCL INCLM: 426/042.000
 INCLS: 426/041.000; 426/656.000; 426/657.000; 426/800.000
 NCL NCLM: 426/042.000
 NCLS: 426/041.000; 426/656.000; 426/657.000; 426/800.000
 IC [6]
 ICM A23C009-12
 IPCI A23C0009-12 [ICM,6]
 IPCR A23L0002-52 [I,C*]; A23L0002-52 [I,A]; A23J0003-00 [I,C*];
 A23J0003-08 [I,A]; A23L0001-305 [I,C*]; A23L0001-305 [I,A];
 A61K0035-20 [I,C*]; A61K0035-20 [I,A]; A61K0038-00 [I,C*];
 A61K0038-00 [I,A]; A61K0038-01 [I,C*]; A61K0038-01 [I,A];
 A61K0038-17 [I,C*]; A61K0038-17 [I,A]; A61P0019-00 [I,C*];
 A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0043-00 [I,C*];
 A61P0043-00 [I,A]; C12N0009-48 [I,C*]; C12N0009-48 [I,A];
 C12N0009-76 [I,C*]; C12N0009-76 [I,A]; C12N0009-94 [I,C*];
 C12N0009-94 [I,A]; C12P0021-06 [I,C*]; C12P0021-06 [I,A]
 EXF 426/41; 426/42; 426/34; 426/656; 426/580; 426/55; 426/56; 426/657;
 426/800; 426/801; 426/810; 435/192
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 116 ab

L16 ANSWER 1 OF 14 USPATFULL on STN
 AB The present invention concerns compositions and methods for the treatment of disorders characterized by the overexpression of an LIV-1. More specifically, the compositions include DNA and amino acid sequences of an LIV-1, antibodies to an LIV-1, and methods for the treatment of a mammal susceptible to or diagnosed with cancer wherein an LIV-1 is overexpressed.

=> d 116 14 ab

L16 ANSWER 14 OF 14 USPATFULL on STN
 AB A bone reinforcing agent comprising a basic protein fraction or a basic peptide fraction derived from milk as an effective component is described. The basic protein fraction is obtained by passing milk or a raw material derived from milk over a cation exchange resin and eluting the adhered fraction. The basic peptide fraction is obtained by hydrolyzing the basic protein fraction with a protease. The basic protein fraction and basic peptide fraction of the present invention promote the growth of osteoclasts and suppress the resorption of osteoclasts, and thereby strengthening bone when administered orally. The invention is useful for treating or preventing bone diseases such as osteoporosis.

=> d 116 14 kwic

L16 ANSWER 14 OF 14 USPATFULL on STN
 TI Bone reinforcing agent and foods and drinks product containing the same
 AB A bone reinforcing agent comprising a basic protein fraction or a basic peptide fraction derived from milk as an effective component is. . . peptide fraction of the present invention promote the growth of osteoclasts and suppress the resorption of osteoclasts, and thereby strengthening bone when administered orally. The invention is useful for treating or preventing bone diseases such as osteoporosis.
 SUMM The present invention relates to a bone reinforcing agent and food and drink products containing the same,

exhibiting a bone reinforcing activity. Because the bone reinforcing agent and the food and drink products containing the same of the present invention exhibit the effects of promoting the growth of osteoblasts and suppressing bone resorption by osteoblasts, they are useful in treating or preventing various bone diseases such as osteoporosis, bone fractures, rheumatism, and arthritis.

SUMM In recent years, the incidence of bone diseases such as osteoporosis, bone fractures, lumbago, and the like, have increased along with the progressive increase in the elderly population. These diseases are caused by insufficient calcium intake, decreased calcium absorption hormonal imbalance postmenopause, and the like. Increasing the peak bone mass, or the total amount of bone in the body, is considered to be effective in preventing bone diseases such as osteoporosis, bone fractures, lumbago, and the like in aged people. Increasing the peak bone mass is equivalent to strengthening the bone. Controlling bone resorption is also considered to be effective in preventing osteoporosis. Bone synthesis is characterized by a repeated balanced formation-resorption cycle which is called remodeling. Hormonal imbalance postmenopause causes bone resorption to predominate over bone formation, resulting in osteoporosis. Accordingly, bones are reinforced by controlling bone resorption and maintaining bone mass at a certain level.

SUMM . . . calcium salts (e.g. calcium carbonate, calcium lactate or calcium phosphate), milk or whey calcium, and natural calcium agents (e.g. cattle bone meal or egg shell), and the like, are used to strengthen the bones. These agents are individually administered or added. . . excreted without being absorbed by the body. Even if absorbed, calcium may not necessarily be utilized for the improvement of bone metabolism or for the reinforcement of bones because the affinity of calcium for bone differs according to the form of the calcium and types of other nutrients which are taken together with calcium. Vitamin. . . may be accompanied by side effects such as ear noises, headache, and anorexia. Furthermore, the addition of these drugs to food or drink is currently infeasible due to safety, and cost considerations. Therefore, the development of a bone reinforcing agent, or a food or drink product containing a bone reinforcing agent, which can be orally administered over an extended period of time and which directly exhibits the bone growth promoting effect or the bone resorption suppressing effect, and is effective in the treatment or prevention of the osteoporosis, is desirable.

SUMM In view of the above-mentioned problems, the present inventors have undertaken extensive research into the substances contained in various raw food materials which exhibit a bone reinforcing effect. This research has resulted in the finding that a basic protein fraction derived from milk or basic peptide. . . as pepsin or pancreatin, exhibit the effects of promoting growth of osteoblasts and suppressing resorption of osteoclasts, and can strengthen bone when administered orally. The inventors of the present invention have found that the basic protein fractions and the basic peptide fraction can be used as a bone reinforcing agent or as an effective component for bone reinforcing food and drinks. These findings have led to the present invention.

SUMM Accordingly, an object of the present invention is to provide a bone reinforcing agent and a food or drink product containing the same, exhibiting the effects of promoting growth of osteoblasts and suppressing resorption of osteoclasts, thereby strengthening bone without causing side effects.

SUMM The object of the present invention is to obtain a bone reinforcing agent or a food or drink product

containing the same which contains a basic protein fraction derived from milk or a basic peptide fraction obtained by. . .

SUMM Specifically, the present invention relates to a bone reinforcing agent which contains a basic protein fraction derived from milk or a basic peptide fraction obtained by hydrolyzing this. . .

SUMM The present invention further relates to a bone reinforcing food or drink product which contains the basic protein fraction or the basic peptide fraction, as an effective component.

DRWD FIG. 3 shows the osteoclast bone resorption suppressing activity of the basic protein fraction and the basic peptide fraction of the present invention in Test Example. . .

DETD . . . a basic peptide fraction obtained by hydrolyzing the basic protein fraction with a protease, as an effective component of a bone reinforcing agent or a food or drink containing the same. The basic protein fraction can be obtained from the milk of a mammal such as a cow. . . peptide fraction can be obtained by hydrolyzing the basic protein fraction with a protease. These fractions act directly on the bone to exhibit a bone reinforcing effect and a bone resorption suppressing effect, and thereby strengthen the bone. As later described in detail in the Test Examples 1-4, the basic protein fraction derived from milk has the following. . .

DETD 3) The major proteins are lactoferrin and lactoperoxidase.

DETD The basic protein fraction or the basic peptide fraction, which is the effective component of the bone reinforcing agent of the present invention, may be administered as is or in suitable forms such as powder, granules, tablets, . . . or after it has been processed into suitable forms, into nutrients, drinks, or foods, to strengthen the bones by promoting bone formation or suppressing bone resorption. Because the milk-derived basic protein fraction and the basic peptide fraction of the present invention are comparatively stable with. . .

DETD . . . Tests using rats confirmed that the amount of the basic protein fraction or the basic peptide fraction for exhibiting the bone reinforcing effect is 0.1% by weight or more in feed. Accordingly, the bone reinforcing effect can be illicit by administering the basic protein fraction or the basic peptide fraction at a dose of 0.5 g/day or more to an adult, who generally takes 500 g/day on a dry basis of food and drink.

DETD Because the bone reinforcing agent and the food or drink containing the same of the present invention promote bone formation and suppress bone resorption, the bones are reinforced if they are administered. Accordingly, the bone reinforcing agent and the food or drink containing the same are useful for treating or preventing various bone diseases, such as osteoporosis, bone fractures, rheumatism, and arthritis and are particularly effective in treating or preventing osteoporosis. Further, it is possible to increase the peak bone mass in the growth period by administering the bone reinforcing agent or a food or drink containing the same of the present invention to infants and children.

DETD . . . in Example 1 was analyzed. The results are shown in Table 2. These results indicate that the basic protein fraction contains 40 wt. % or more of lactoferrin and 40 wt. % or more of lactoperoxidase.

DETD

TABLE 2

	(wt. %)
Lactoferrin	42.5
Lactoperoxidase	45.6
Insulin-like growth factor-I	

factor-I	0.005
Others	11.895

DETD Femora were extirpated from rabbits (age: 10 days) and the soft tissues were removed. All the bone marrow cells containing osteoclasts, prepared by mechanically pulverizing the femora in a medium containing 5% FBS, were plated over a . . . with 10% of a solution prepared by diluting the liquid collected from the insides of each inverted gut sac threefold. Bone resorption pits created on the ivory were stained with hematoxylin and counted to determine the effect of suppressing osteoclast resorption. . .

DETD . . . which only the Ringer's solution was used as the external solution. These results confirmed that the effective component of the bone reinforcing agent of the present invention can pass through the gastrointestinal tract.

DETD The bone reinforcing effect of the basic protein fraction obtained in Example 2 was measured in experiments using animals.

DETD . . . 300 mg of calcium, 230 mg of phosphorous, and 50 mg of magnesium were added to each 100 g of food.

DETD After 4 weeks, both the femora and tibiae were extirpated. The breaking force of the femora was measured using a bone fracture properties measuring device (Rheometer Max RX-1600, trademark, manufactured by Aitekno Co. Ltd.). The tibiae were electrically demineralized and stained. . .

DETD A bone reinforcing drink of the composition shown in Table 5 was prepared.

DETD A paste with a composition shown in Table 6 was formed and baked to make a bone reinforcing biscuit.

DETD Tablets of bone reinforcing agent with a composition shown in Table 7 were prepared.

CLM What is claimed is:

1. A bone reinforcing agent comprising, as an effective component, a basic protein fraction derived from milk having an amino acid composition containing. . .

CLM What is claimed is:

2. The bone reinforcing agent according to claim 1, wherein the basic protein fraction derived from milk is obtained by contacting milk or. . .

CLM What is claimed is:

3. A bone reinforcing agent comprising, as an effective component, a basic peptide fraction having an average molecular weight of 4,000 Da or. . .

CLM What is claimed is:

4. The bone reinforcing agent according to claim 3, wherein the protease is selected from the group consisting of pepsin, trypsin, and chymotrypsin. . .

CLM What is claimed is:

5. The bone reinforcing agent according to claim 3, wherein the protease is pancreatin and at least one protease selected from the group. . .

CLM What is claimed is:

6. The bone reinforcing agent according to claim 1, which exhibits effects of promoting growth of osteoblasts and suppressing resorption of osteoclasts.

CLM What is claimed is:

7. A food or drink composition comprising the basic protein fraction derived from milk defined in claims 1 or 3.

=> d hist

(FILE 'HOME' ENTERED AT 20:53:41 ON 20 JUN 2008)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 20:53:49 ON 20 JUN 2008
SEA LACTOPEROXIDASE AND OSTEO?

1 FILE AGRICOLA
9 FILE BIOSIS
1 FILE BIOTECHABS
1 FILE BIOTECHDS
2 FILE BIOTECHNO
3 FILE CABA
13 FILE CAPLUS
1 FILE DGENE
2 FILE DRUGU
10 FILE EMBASE
2 FILE ESBIOBASE
3 FILE FROSTI
3 FILE FSTA
4 FILE IFIPAT
2 FILE LIFESCI
5 FILE MEDLINE
1 FILE PASCAL
2 FILE PROMT
5 FILE SCISEARCH
3 FILE TOXCENTER
587 FILE USPATFULL
97 FILE USPAT2
8 FILE WPIDS
8 FILE WPINDEX

L1 QUE LACTOPEROXIDASE AND OSTEO?

SEA L1 AND (FOOD OR DRINK OR DRUG OR FEED)

1 FILE BIOSIS
1 FILE BIOTECHNO
1 FILE CABA
5 FILE CAPLUS
1 FILE DGENE
1 FILE DRUGU
7 FILE EMBASE
1 FILE FSTA
2 FILE IFIPAT
1 FILE MEDLINE
2 FILE PROMT
1 FILE SCISEARCH
1 FILE TOXCENTER
475 FILE USPATFULL
84 FILE USPAT2
6 FILE WPIDS
6 FILE WPINDEX

L2 QUE L1 AND (FOOD OR DRINK OR DRUG OR FEED)

FILE 'BIOSIS, BIOTECHNO, CABA, CAPLUS, DGENE, DRUGU, EMBASE, FSTA, IFIPAT, MEDLINE, PROMT, SCISEARCH, TOXCENTER, USPATFULL, USPAT2' ENTERED
AT 20:56:16 ON 20 JUN 2008

L3 584 S L2
 L4 581 DUP REM L3 (3 DUPLICATES REMOVED)
 L5 474 S L4 AND DIGEST?
 L6 107 S L5 AND OSTEOBLAST?
 L7 103 S L6 AND PROMOT?
 L8 98 S L7 AND INDUC?
 L9 28 S L8 AND OSTEOGENESIS
 L10 1 S OSTEOBLAST PRODUC? AND LACTOPEROXIDASE

FILE 'USPATFULL' ENTERED AT 21:01:45 ON 20 JUN 2008

L11 0 S LACTOPEROXIDASE IN FOOD
 L12 0 S FOOD CONTAINING LACTOPEROXIDASE
 L13 707 S FOOD AND LACTOPEROXIDASE
 L14 191 S L13 AND (DRINK OR FEED)
 L15 88 S L14 AND CONTAIN?(P)LACTOPEROXIDASE
 L16 14 S L15 AND BONE

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
30.30	112.88

FULL ESTIMATED COST

STN INTERNATIONAL LOGOFF AT 21:07:22 ON 20 JUN 2008